Picture of argenx SE logo

ARGX argenx SE Share Price

0.000.00%
be flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Momentum

Relative Strength (%)
1m+4.49%
3m+18.5%
6m+66.97%
1yr+25.69%
Volume Change (%)
10d/3m+13.3%
Price vs... (%)
52w High-0.84%
50d MA+10.36%
200d MA+36.17%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)72.07
PEG Ratio (f)0.79
EPS Growth (f)972.79%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value8.84
Price to Tang. Book9.15
Price to Free Cashflown/a
Price to Sales30.74
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-9.89%
Return on Equity-8.29%
Operating Margin-34.66%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m78.4641.24497.28410.751,226.322,121.263,185.34117.25%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/an/an/a+658.05n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of argenx SE EPS forecast chart

Profile Summary

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Directors

Last Annual
December 31st, 2023
Last Interim
September 30th, 2024
Incorporated
April 25th, 2008
Public Since
July 10th, 2014
No. of Employees
1,148
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
be flag iconEuronext - Brussels
Shares in Issue
60,367,650
Blurred out image of a map
Address
Laarderhoogtweg 25, AMSTERDAM, 1101 EB
Web
https://www.argenx.com/
Phone
+31 763030
Auditors
Deloitte Accountants B.V.

ARGX Share Price Performance

Upcoming Events for ARGX

Q4 2024 argenx SE Earnings Release

argenx SE Annual Shareholders Meeting

Q1 2025 argenx SE Earnings Release

Similar to ARGX

Picture of Celyad Oncology SA logo

Celyad Oncology SA

be flag iconEuronext - Brussels

Picture of Oxurion NV logo

Oxurion NV

be flag iconEuronext - Brussels

Picture of Sequana Medical NV logo

Sequana Medical NV

be flag iconEuronext - Brussels

FAQ